SCN9A Antikörper (AA 1751-1946)
Kurzübersicht für SCN9A Antikörper (AA 1751-1946) (ABIN361773)
Target
Alle SCN9A Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 1751-1946
-
Spezifität
- Detects ~230 kDa. No cross-reactivity against other Nav channels.
-
Kreuzreaktivität
- Hamster, Human, Maus, Ratte
-
Aufreinigung
- Protein G Purified
-
Immunogen
- Fusion protein amino acids 1751-1946 (C-terminus) of human Nav1.7
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
-
- WB (1:1000)
- IHC (1:1000)
- ICC/IF (1:100)
- optimal dilutions for assays should be determined by the user.
-
Kommentare
-
1 μg/ml of ABIN361773 was sufficient for detection of Nav1.7 in 10 μg of HEK-293 cell lysate transiently expressing Nav1.7 by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 mg/mL
-
Buffer
- PBS pH 7.4, 50 % glycerol, 0.09 % sodium azide, Storage buffer may change when conjugated
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- -20°C
-
-
-
: "Effects of HIV-1 Tat on enteric neuropathogenesis." in: The Journal of neuroscience : the official journal of the Society for Neuroscience, Vol. 34, Issue 43, pp. 14243-51, (2014) (PubMed).
-
-
- SCN9A (Sodium Channel, Voltage-Gated, Type IX, alpha Subunit (SCN9A))
-
Andere Bezeichnung
- Nav1.7
-
Hintergrund
- Nav1.7 is a voltage-gated sodium channel and plays a critical role in the generation and conduction of action potentials and is thus important for electrical signaling by most excitable cells. Therapeutically, the association of pain insensitivity with the loss of function of a certain sodium channel may have implications. Since Nav1.7 is not present in cardiac muscle or neurons in the central nervous system, blockers of Nav1.7 will not have direct action on these cells and thus can have less side effects than current pain medications. By performing more studies, there is a possibility to develop a new generation of drugs that can reduce the pain intensity in animals (1-3).
-
Gen-ID
- 6335
-
NCBI Accession
- NP_002968
-
UniProt
- Q15858
Target
-